ArticleBlood neoplasia2026
High cancer-associated mutational burden in normal blood of xeroderma pigmentosum group C, but not groups A, D, or F.
Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Xeroderma pigmentosum (XP) is a rare autosomal recessive congenital syndrome characterized by defective nucleotide excision repair (NER), leading to extreme photosensitivity and a strong predisposition to skin cancer. One of the 8 complementation groups, XP complementation group C (XP-C), is defective specifically in the global genome component of NER and presents not only with increased skin cancer but also with hematologic cancers. Using error-corrected single-molecule sequencing, we show a uniquely high spontaneous somatic mutational load in peripheral blood mononuclear cells (PBMCs) of patients with XP-C but not in those of patients from other XP complementation groups (XP-A, XP-D, and XP-F). The hypermutability observed in XP-C was markedly lower in fibroblasts than in PBMCs. The XP-C mutational profile was characterized by elevated single-nucleotide variants (SNVs) associated with mutational signatures SBS5, SBS8, and SBS32, as well as an enrichment of single-nucleotide cytosine deletions, with SNV profiles closely mirroring those found in XP-C leukemias. These findings indicate that a cancer-like mutation burden is already present in normal lymphocytes before malignant transformation, revealing distinct molecular subtypes within XP defined by spontaneous mutational load in normal blood cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.